Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
It's PR from the company, something we have criticized them for a lack of.
They would obviously look at cash available and highlight the need this year.
It's whether we do it now or post COVID results. I personally think it will be before the POC to allow other long term investors in at a discount price before we enter the inflection point mentioned.
2p placing would be acceptable and we'll bounce straight back if we have funding for our own CTA through to completion.
We won't deal before CTA announced, it must go to CTA so the purchaser can't screw with it.
The interesting element will be the willingness of UK gov to invest in and buy the pills in advance. A very real possibility and lessons have already been learnt with regards to this strategy.
Nothing to stop a large government contract being in place upon a successful lab study.
This isn't like a mask, where they can get their mates the contracts, if it is proposed by UKRI then it's happening.
We need more dialogue on this from the bod at the next meeting.
I'm even more confident of a 3p target by next week now. I managed to top up this morning, reported as a sell to contribute to the earlier topic on sells being buys, that information is correct as per Laz posts.
From memory Parker has the occasional tweet,but it's mostly retweet and no actual effort, this is the most bullish I've seen Parker.
As for interest, don't worry about that and enjoy the peace and genuine postings while we can, as mentioned this could change in the blink of an eye and the majority of people/investors don't look at a mcap, they'll just look at previous history with the COVID stocks. 2p to x, nothing is impossible here.
Good luck to all the genuine investors and newbies for.the coming weeks.
Hoping for a bit of meat on the Sareum tyk2 bone, looks like the target is already proven. All good signs for a positive outcome from our lab study.
https://www.sciencedaily.com/releases/2021/03/210310122514.htm
Hi Thoth, 8weeks can't come quick enough - if we have to wait that long. My only concern is that why haven't the other tyk2 players made their compounds available. If the research is right then BMS has the better compound in theory.
BMS have some data on their TYK2 out next week, 22nd I believe.
It actually gets better and I've not noticed this before. So the study is down as being a "Collaborative R&D" who exactly are we collaborating with as it certainly hasn't been announced. They are normally classified as a feasibility study.
I think you meant to post this Bobbler : https://gtr.ukri.org/projects?ref=83721
I know we've seen this article a few times, but to have our very own UKRI, who supplied our grant make the publication tells us that this is going further:
https://www.ukri.org/news/five-genes-identified-that-could-be-key-to-new-covid-19-treatments/
Then Dr. Kenneth Baillie, the chief investigator is quoted saying "Our results immediately highlight which drugs should be at the top of the list for clinical testing. We can only test a few drugs at a time, so making the right choices will save thousands of lives."
Therefore TYK2 is top of the list. Simples.
Here's the timescale for a phase 1 in COVID for a new treatment:
https://clinicaltrials.gov/ct2/show/NCT04756531
3months with 60people.
POC in June/July
P1 complete October/Novemeber
Compound (0) is actually the same as the already granted patent - unfortunately, I don't have time to compare the rest at the minute but very interesting and thanks againCitizen
More Patents means we have tweaked the compound and need to provide patent protection, it's not a flaw in another patent or molecule, more a specific tweak to further target a specific disease.
It's good news for sure and since 1802 is fully patented and is in essence a similar compound it will be a formality and may even lead to a quicker granting of other patents.
Ref: http://www.sareum.com/news/press-releases-and-news/2021/us-patent-grant-tyk2jak1-anticancer-candidate/
Not an expert but I'm quite sure we will only be relevant to serious ill patients if COVID and not for long COVID. Reason being we have read that IFNAR2 is underexpressed in COVID patients and our tyk2 will inhibit this, so that's a negative. That's why it is important to treat at the right time, but this is all academic literature at the moment, the lab studies will provide a greater insight and allow Sareum to identify the best time to treat with sdc1801 to inhibit tyk2 before disease progresses to mechanical ventilation.
IFNAR2 helps with the initial defence of COVID as far as I understand it. It would be worth actually checking how much we inhibit this. Also worth noting that we have multiple tyk2 variants for selectivity, the lab study should be testing a multitude of them.
My only concern with this and I still don't know why - why haven't BMS, Nimbus or Pfizer put their tyk2s in the mix.. BMS would avoid IFNAR2 completely...
Novice, welcome and don't put yourself down, I'm sure having L2 you have knowledge, so post more.
Yesterdays daily high is now breached so the positive sentiment remains, and should remain for some time, with the slight stops on the journey.
Chk1 provides any potential buyer of Sareum with these income streams as Thoth states which as it progresses should make Sareum an extremely valuable company. We've done the leg work up front, we have a 28.5% share of the asset and it's about to progress to the final stage. Sareum could sit and do nothing as company and we would all be very happy shareholders living off dividends from Chk1 / tyk2. Priceless
Hi Thoth, there is urgency and that is what we need to transpire at Sareum. A much greater urgency, they have taken their time on the design and the pre-clinical work to generate a license package. It should be full steam ahead and remember SDC-1802 will play catch up as will go directly into cancer patients.
I remain very confident for the next weeks and months, unless an unexpected event in the half yearly then it's certainly onwards and upwards.
Phil, well done on getting the bed&isa through, don't be put off by the price above 2p and buying, as the saying goes, buy high, sell higher. Trade the trend, and everything is pointing to a move North - once the day traders get onboard after a positive RNS this will confirm the movement, and off we go.
Hi Aber, with regards to the CTA I think that the delay is because we have initiated a new study, COVID study with SDC-1801. If you read back on the Q&A from investor meet company John mentions that the regulator wants to see all data available for the compound if you have it, even if it is not related to the target indication, which we still don't know.